Annex tables to the European Drug Report 2026

These tables, produced specifically for the European Drug Report, provide national data for estimates of drug use prevalence including problem opioid use, opioid substitution treatment, total number in treatment, treatment entry, injecting drug use, drug-induced deaths, drug-related infectious diseases, syringe distribution and drug seizures. The data are drawn from and are a subset of the Statistical Bulletin 2026, where notes and meta-data are available. The years to which data refer are indicated. In addition, for some indicators, these data tables also provide total values for the European Union as well as for all EUDA reporting countries (EU Member States, Türkiye and Norway).

This page is part of the European Drug Report 2026, the EUDA’s annual overview of the drug situation in Europe.

Last update: 9 June 2026

List of tables

Opioids

Table 1a. High-risk opioid use estimates for the population aged 15 to 64 years (European Drug Report 2026)

Notes

High-risk opioid use estimates relate to the population aged 15 to 64 years, except for Italy (15 to 84).

Table 1b. Entrants into treatment during the year: opioids clients as a proportion of treatment demands (European Drug Report 2026)

Notes

Data on entrants into treatment are for 2024 or most recent year available: Spain, France, Türkiye, 2023. For entrants into treatment during the year, percentages shown are for entrants for which the substance is known.
Norway: The percentage of clients in treatment for opioid-related problems is a minimum value, not accounting for opioid clients registered as polydrug users.

Table 1c. Entrants into treatment during the year: proportion of opioids clients with injection as main route of administration (European Drug Report 2026)

Notes

Data on entrants into treatment are for 2024 or most recent year available: Spain, France, Türkiye, 2023. For entrants into treatment during the year, percentages shown are for entrants for which the substance is known. Missing cases of 30% or more for main route of administration: Czechia, Germany, France, the Netherlands. 
Sweden: Data for main route of administration are for compulsory institutional care only, therefore not representative of the national picture.

Table 1d. Number of clients in opioid agonist treatment (European Drug Report 2026)

Notes

Data on clients in agonist treatment are for 2024 or most recent year available: Italy, 2018; Hungary, 2022; Netherlands, Spain, Türkiye, 2023.

Czechia: Number of clients in agonist treatment is an estimate derived from the treatment demand register and opioid agonist treatment provided by general practitioners.
Netherlands: Data on the number of clients in agonist treatment are not complete.

Cocaine

Table 2a. Cocaine prevalence (percent) estimates among the general population and school students (European Drug Report 2026)

Notes

Prevalence estimates for the general population: age ranges are 18-64 and 18-34 for Germany, Greece, France, Italy and Hungary; 16-64 and 16-34 for Denmark, Estonia and Norway; 17-34 for Sweden; 18-65 and 18-34 for Malta.
Prevalence estimates for the school population are extracted from the 2024 ESPAD survey, except for Belgium (2024, VAD School Survey – Flanders only), Luxembourg (2022, HBSC), Portugal (2024, ECATD-CAD), Spain (2025, ESTUDES) and Sweden (2024, CAN Survey). ESPAD data for Germany refer to Bavaria only. Age range is 15-16.

Table 2b. Entrants into treatment during the year: cocaine clients as a proportion of treatment demands (European Drug Report 2026)

Notes

Data on entrants into treatment are for 2024 or most recent year available: Spain, France, Türkiye, 2023. For entrants into treatment during the year, percentages shown are for entrants for which the substance is known. 

Table 2c. Entrants into treatment during the year: proportion of cocaine clients with injection as main route of administration (European Drug Report 2026)

Notes

Data on entrants into treatment are for 2024 or most recent year available: Spain, France, Türkiye, 2023. For entrants into treatment during the year, percentages shown are for entrants for which the substance is known.
Missing cases of 30% or more for main route of administration: Germany, France, the Netherlands.
Sweden: Data for main route of administration are for compulsory institutional care only, therefore not representative of the national picture.

Amphetamines

Table 3a. Amphetamines prevalence (percent) estimates among the general population and school students (European Drug Report 2026)

Notes

Prevalence estimates for the general population: age ranges are 18-64 and 18-34 for Germany, France, Italy and Hungary; 16-64 and 16-34 for Denmark, Estonia and Norway; 17-34 for Sweden; 18-34 for Malta.
Prevalence estimates for the school population are extracted from the 2024 ESPAD survey. ESPAD data for Germany refer to Bavaria only. Data refer only to amphetamine. Age range is 15-16.

Table 3b. Entrants into treatment during the year: amphetamines clients as a proportion of treatment demands (European Drug Report 2026)

Notes

Data on entrants into treatment are for 2024 or most recent year available: Spain, France, Türkiye, 2023. For entrants into treatment during the year, percentages shown are for entrants for which the substance is known.
Sweden: Data on entrants into treatment are for ‘stimulants other than cocaine’.
Norway: Data treatment entrants are for 'stimulants other than cocaine'.
 

Table 3c. Entrants into treatment during the year: proportion of amphetamines clients with injection as main route of administration (European Drug Report 2026)

Notes

Data on entrants into treatment are for 2024 or most recent year available: Spain, France, Türkiye, 2023. For entrants into treatment during the year, percentages shown are for entrants for which the substance is known. Missing cases of 30% or more for main route of administration: Germany, France, the Netherlands.   
Sweden: Data for main route of administration are for compulsory institutional care only, therefore not representative of the national picture. 
Norway: Data treatment entrants are for 'stimulants other than cocaine'.

MDMA

Table 4a. MDMA prevalence (percent) estimates among the general population and school students (European Drug Report 2026)

Notes

Prevalence estimates for the general population: age ranges are 18-64 and 18-34 for Germany, Greece, France, Italy and Hungary; 16-64 and 16-34 for Denmark, Estonia and Norway; 17-34 for Sweden; 18-65 and 18-34 for Malta.
Prevalence estimates for the school population are extracted from the 2024 ESPAD survey, except for Belgium (2025, VAD School Survey – Flanders only), Luxembourg (2024, HBSC), Portugal (2024, ECATD-CAD), Spain (2025, ESTUDES) and Sweden (2024, CAN Survey). ESPAD data for Germany refer to Bavaria only. Age range is 15-16.

Table 4b. Entrants into treatment during the year: MDMA clients as a proportion of treatment demands (European Drug Report 2026)

Notes

Data on entrants into treatment are for 2024 or most recent year available: Spain, France, Türkiye, 2023.  For entrants into treatment during the year, percentages shown are for entrants for which the substance is known.

Cannabis

Table 5a. Cannabis prevalence (percent) estimates among the general population and school students (European Drug Report 2026)

Notes

Prevalence estimates for the general population: age ranges are 18-64 and 18-34 for Germany, Greece, France, Italy and Hungary; 16-64 and 16-34 for Denmark, Estonia, Sweden and Norway; 18-65 and 18-34 for Malta.
Prevalence estimates for the school population are extracted from the 2024 ESPAD survey, except for Belgium (2024, VAD School Survey – Flanders only), Luxembourg (2022, HBSC), Portugal (2024, ECATD-CAD), Spain (2025, ESTUDES) and Sweden (2024, CAN Survey). ESPAD data for Germany refer to Bavaria only. Due to possible overstating, Luxembourg cannabis lifetime prevalence may be slightly overestimated. Age range all 15-16.

Table 5b. Entrants into treatment during the year: cannabis clients as a proportion of treatment demands (European Drug Report 2026)

Notes

Data on entrants into treatment are for 2024 or most recent year available: Spain, France, Türkiye, 2023. For entrants into treatment during the year, percentages shown are for entrants for which the substance is known.

Other indicators

Table 6. Other indicators: drug-induced deaths, HIV diagnoses, injecting drug use estimates, take-home naloxone, syringes distributed through specialised programmes (European Drug Report 2026)

Notes

Data on drug-induced deaths must be interpreted with caution. Differences in methodology and data completeness should be considered when comparing countries. The average mortality rate for the European Union (and the European Union plus Türkiye and Norway) is computed as the weighted average of the mortality rates for the 27 (or 29) countries in 2024 – or the last available year – using the population aged 15 to 64 in 2024 as weights. France changed the preferred source of data in 2024.
HIV diagnoses related to injecting drug use are from 2024.
Injecting drug use estimates refer to the population aged 15 to 64 years.
Syringes distributed through specialised programmes refer to 2024, except for Germany (2021), Spain (2023), France (2022), Finland (2023) and Norway (2022).
Naloxone is available over the counter in Denmark, France, Italy and Sweden. In France, the latest numbers (2021) include kits given for free by harm reduction and treatment facilities to their clients and kits ordered by pharmacies. In Luxembourg, since September 2024, all high-risk drug users and people injecting drugs in one closed prison setting should receive a kit upon release. In Italy, availability is limited to a small number of regions.

Seizures of drugs

Table 7. Seizures data (European Drug Report 2026)

Notes

All data are for 2024 or the most recent year and are rounded off to the most significant figures.
France: The figure for amphetamine seizures, 618 kilograms, includes both amphetamine and methamphetamine.
Netherlands: In 2024, the data concern seizures by Dutch Customs only. No data on seizures by the police are available. As a result, these figures provide only a partial picture of the total number of seizures. Since 2017, the data represent a minimum amount, therefore seizures data are incomplete.
Amphetamine (including captagon) and methamphetamine tablets were converted to mass-equivalents by assuming a mass of 0.25 grams per tablet. 
Methamphetamine: methamphetamine/methylamphetamine. 

 

Source data (CSV format)

The data used to create these tables may be found in CSV (comma-separated values) format below.

The complete set of source data for the European Drug Report 2026, including metadata and methodological notes, is available in our data catalogue.

A subset of the data used to generate the tables on this page may be found below.

View this data in our Data catalogue
Download all files (zip)  
Main subject
Keywords
Target audience
Publication type
European Drug Report 2026 main page
On this page
Top